Cure Alzheimer's Fund Appoints Four Experts to Scientific Advisory Board
Cure Alzheimer's Fund (CureAlz) has added four new members to its Scientific Advisory Board. The new members are recognized experts in therapeutics development for Alzheimer's disease.
Wellesley Hills, Massachusetts – Cure Alzheimer's Fund (CureAlz), a non-profit organization focused on Alzheimer's disease research, announced the appointment of four new members to its Scientific Advisory Board. The appointees include Dr. Michelle Arkin, Dr. Ronald B. DeMattos, Dr. Donna M. Huryn, and Dr. Justin M. Schultze.
The expansion of the board is expected to enhance CureAlz's capacity to evaluate and advance promising research initiatives aimed at developing treatments for Alzheimer's disease. The organization plays a key role in funding and providing strategic direction for Alzheimer's research.
CureAlz is dedicated to accelerating breakthroughs in the development of therapies for Alzheimer's. The fund supports a wide range of research areas with the objective of finding effective treatments for the condition.
The Scientific Advisory Board is instrumental in shaping the fund's research strategy and guiding its funding decisions. The newly appointed members bring extensive experience in drug development and therapeutic strategies.